One Health Initiative Webinar Series: Part 2

One Health -- Use of in silico models to promote an understanding drug pharmacokinetics and for formulation optimization

Click to view the recording!

Broadcast Date: Thursday, August 18th | 11:00 a.m. - 12:00 p.m. Eastern

From a therapeutics perspective, the One Health Initiative is integrally related to the development of formulations that are consistent with the attributes of the drug, that will provide the necessary rate and extent of drug exposure, and that is appropriate for targeted patient population. The second webinar in this three-part series will examine the utility of a mechanistic approach to formulation development. Using the ADMET Predictor™, GastroPlus™ and DDDPlus™ software as a platform for discussions, this webinar will showcase the use of in silico approach to integrate drug physicochemical properties; knowledge about mechanisms involved in drug’s absorption, distribution and elimination; and information obtained from in vitro and preclinical studies into predictions that can be used to optimize a formulation to meet specific patient needs. Included will be discussions of software that can be used to evaluate the physicochemical properties of a compound from its chemical structure, predict solubility in biorelevant media, predict membrane permeability and facilitate formulation optimization.

What attendees will take away:

  • Computer-based mechanistic models are an invaluable tool for facilitating an integration of information derived from in vivo and in vitro sources.
  • In silico models are useful in providing early predictions of drug’s behavior in vivo based on the structure of the compound.
  • Mechanistic models are invaluable in translating the drug’s behavior in vivo across species and populations as well as optimizing the formulation for target population.

Who should attend this webinar?

Individuals involved with the development and use of therapeutic products from the perspective of biopharmaceutics, pharmacokinetics, dose-exposure-response relationships, and interspecies extrapolations (including researchers from academia, industry, and government); physicians; veterinarians; students (human or veterinary medicine, university); environmental scientists.

About the Speaker

Dr. Viera Lukacova, Simulations Plus, Inc., Lancaster, California, U.S.A.
Dr. Lukacova is a team leader of Simulations Technologies team at Simulations Plus, Inc. She has been the lead scientist, software developer, and Product Manager for GastroPlus for over ten years, and is recognized as a global leader and innovator in PBPK modeling and simulation. She authored a number of papers in computational chemistry, basic research of transport of small molecules through artificial membranes, and pharmacokinetic and pharmacodynamic modeling in peer-reviewed journals and served as a reviewer of publications in the same areas.

© Copyright Controlled Release Society  | Contact Us - Report a Bad Link